Steven Gallinger

Director, PanCuRx

Dr. Steven Gallinger leads OICR’s Translational Research Initiative focused on pancreatic cancer (PanCuRx). He is a Hepatobiliary/pancreatic (HPB) surgical oncologist at the Princess Margaret Cancer Centre, Professor of Surgery at the University of Toronto and lead of the HPB Surgical Oncology Program at both the University Health Network and Mount Sinai Hospital.

Dr. Gallinger is also the co-Director of the Centre for Cancer Genetics at the Samuel Lunenfeld Research Institute, co-Principal Investigator of the Zane Cohen Familial Gastrointestinal Cancer Registry, Principal Investigator of the Ontario Pancreas Cancer Study, a member of the NIH funded Pancreas Cancer Genetic Epidemiology consortium, a population-based registry of pancreas cancer cases and their families which is now integrated with the International Cancer Genome Consortium (ICGC). His research is focused on gastrointestinal (GI) cancer genetics – both the inherited and acquired molecular aspects of colorectal and pancreatic cancer.

Current affiliations

  • Director, PanCuRx TRI, OICR;
  • Surgical Oncologist, University Health Network;
  • Head, Hepatobiliary/Pancreatic Surgical Oncology Program, University Health Network;
  • Senior Investigator, Samuel Lunenfeld Research Institute of Mount Sinai Hospital;
  • Member, Institute of Medical Sciences, School of Graduate Studies, University of Toronto;
  • Professor, Department of Surgery, University of Toronto, Toronto, ON;
  • Member, Department of Laboratory Medicine and Pathobiology, University of Toronto;
  • Co-Director, Zane Cohen Digestive Diseases Clinical Research Centre, Mount Sinai Hospital, Toronto, ON;
  • Active Staff, General Surgery, Toronto General Hospital, Toronto, Ontario;
  • Co-Director, Centre for Cancer Genetics, Lunenfeld-Tanenbaum Research Institute, Toronto, ON;
  • Head, Hepatobiliary Pancreatic Surgical Oncology, University Health Network/ Mount Sinai Hospital, Princess Margaret Hospital, Toronto General Hospital;

Research interests

  • Hepatobiliary/pancreatic cancers;
  • Cancer genetics.

Select publications

Aung K, Fischer S, Denroche R, Jang G, Dodd A,  Creighton S, Southwood B, Liang S, Chadwick D, Zhang A, O’Kane G, Albaba H, Moura S, Grant R, Miller J,  Mbabaali F, Pasternack D, Lungu I, Bartlett J, Ghai S, Lemire M, Holter S, Connor A, Moffitt R, Yeh J, Timms L, Krzyzanowski P, Dhani N, Hedley D, Notta F, Wilson J, Moore M, Gallinger S, Knox J.
Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial.
Clin Cancer Res. 2018;24(6):1344-1354.

Grant R, Denroche R, Borgida A, Virtanen C, Cook N, Smith A, Connor A, Wilson J, Peterson G, Roberts N, Klein A, Grimmond S, Biankin A, Cleary S, Moore M, Lemire M, Zogopoulos G, Stein L, Gallinger S.
Exome-Wide Association Study of Pancreatic Cancer Risk.
Gastroenterology. 2018;154(3):719-722.e3.

Connor A, Denroche R, Jang G, Timms L, Kalimuthu S, Selander I, McPherson T, Wilson G, Chan-Seng-Yue M, Borozan I, Ferretti V, Grant R, Lungu I, Costello E, Greenhalf W, Palmer D, Ghaneh P, Neoptolemos J, Buchler M, Petersen G, Thayer S, Hollingsworth M, Sherker A, Durocher D, Dhani N, Hedley D, Serra S, Pollett A, Roehrl M, Bavi P, Bartlett J, Cleary S, Wilson J, Alexandrov L, Moore M, Wouters B, McPherson J, Notta F, Stein L, Gallinger S.
Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma.
JAMA Oncol. 2017;3(6):774-783.

Notta F, Chan-Seng-Yue M, Lemire M, Li Y, Wilson G, Connor A, Denroche R, Liang S, Brown A, Kim J, Wang T, Simpson J, Beck T, Borgida A, Buchner N, Chadwick D, Hafezi-Bakhtiari S, Dick J, Heisler L, Hollingsworth M, Ibrahimov E, Jang G, Johns J, Jorgensen L, Law C, Ludkovski O, Lungu I, Ng K, Pasternack D, Petersen G, Shlush L, Timms L, Tsao M, Wilson J, Yung C, Zogopoulos G, Bartlett J, Alexandrov L, Real F, Cleary S, Roehrl M, McPherson J, Stein L, Hudson T, Campbell P, Gallinger S.
A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns.
Nature. 2017;542(7639):124.

Holter S, Borgida A, Dodd A, Grant R, Semotiuk K, Hedley D, Dhani N, Narod S, Akbari M, Moore M, Gallinger S.
Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma.
J Clin Oncol. 2015;33(28):3124-9.

See Dr. Gallinger’s recent publications on PubMed.

Patents

Animal Model of the Human Immune System.  Gallinger S, Hozumi N, Roder J, Sandhu J, Shpitz B: US Patent –Patent #08/102,905. 1996.

Assessment of Risk for Colorectal Cancer. Cotterchio M, Gallinger S, Greenwood C, Hudson TJ, Zanke BW, Phillips M, Sundararajan S, Montpetit A, Laflamme P, Ferretti V.  Patent # PCT/CA 2008/000424. Pub # WO/2008/106785. 2008.

Awards

  • University Health Network, The Joseph and Wolf Lebovic Chair in HPB Surgery, 2014;
  • Oakdale Golf and Country Club/George Knudson Research Chair in Gastrointestinal Cancer, 2008;
  • University Health Network, Division of Surgery, Frank Mills Award, 2006;
  • University of Toronto, Department of Surgery, 4th Annual Charles H. Tator Surgeon-Scientist Mentoring Award, 2005;
  • University of Edinburgh, James IV Travelling Fellowship, 2005;
  • University of Toronto, Department of Surgery, Lister Prize, 2003;
  • Israel Cancer Research Fund, Scientific Award, 2001;
  • Mount Sinai Hospital, Lloyd S. Fogler Award, 2000;
  • University of Toronto, Department of Surgery, George Armstrong Peters Prize, 1995.

Previous experience and education

  • FRCS(C);
  • MD, University of Toronto;
  • MSc, University of Toronto.

Related links

Opportunities to collaborate

To collaborate with Dr. Gallinger, please contact him directly.

Visit OICR’s Collaborative Research Resources directory for more opportunities to collaborate with OICR researchers.

Contact

Susan Levitt
Executive Assistant
Susan.Levitt@uhn.ca